Enanta Pharmaceuticals
ENTA
147 hedge funds and large institutions have $1.1B invested in Enanta Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 42 increasing their positions, 71 reducing their positions, and 14 closing their positions.
5,408% more call options, than puts
Call options by funds: $2.92M | Put options by funds: $53K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more capital invested
Capital invested by funds: $827M → $1.1B (+$274M)
2.74% more ownership
Funds ownership: 93.2% → 95.94% (+2.7%)
3% less funds holding
Funds holding: 151 → 147 (-4)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
41% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$46.3M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$15.3M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$9.02M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$6.87M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$8.65M |
| 2 |
AC
Armistice Capital
New York
|
-$8.11M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.35M |
| 4 |
Millennium Management
New York
|
-$6.19M |
| 5 |
BlackRock
New York
|
-$3.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
151
Trexquant Investment
Stamford,
Connecticut
| – | -$350K | -7,958 | Closed |
|
|
6M
152
6 Meridian
Wichita,
Kansas
| – | -$325K | -7,390 | Closed |
|
|
AIM
153
Aigen Investment Management
New York
| – | -$307K | -6,987 | Closed |
|
154
Fisher Asset Management
Camas,
Washington
| – | -$291K | -6,601 | Closed |
|
|
GCP
155
GSA Capital Partners
London,
United Kingdom
| – | -$276K | -6,281 | Closed |
|
|
RA
156
Royce & Associates
New York
| – | -$235K | -5,340 | Closed |
|
157
Squarepoint
New York
| – | -$217K | -4,924 | Closed |
|
|
ECM
158
Everence Capital Management
Goshen,
Indiana
| – | -$210K | -4,780 | Closed |
|
159
Group One Trading
Chicago,
Illinois
| – | -$297 | -6 | Closed |
|
|
GWS
160
Glassman Wealth Services
Vienna,
Virginia
| – | +$247 | +5 | New |
|
ENTA Hedge Fund Activity: Q3 2021 in Review
147 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2021, worth a combined $1.1B — up 33% from $827M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ENTA and 11 opened new positions — a net loss of 3 holders — while 71 trimmed existing stakes and 42 added.
The largest buyer was First Manhattan, adding an estimated $46.3M. The largest seller was Invesco, cutting an estimated $8.65M.
- 147 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2021, down from 151 in Q2 2021.
- Funds reported $1.1B of Enanta Pharmaceuticals stock for Q3 2021, up 33% quarter-over-quarter.
- 11 funds opened new Enanta Pharmaceuticals positions in Q3 2021 and 14 closed out, a net change of -3 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2021 was First Manhattan, an estimated $46.3M added.
- The largest Enanta Pharmaceuticals seller in Q3 2021 was Invesco, an estimated $8.65M sold.
Based on aggregated 13F filings for Q3 2021.